Introduction {#s1}
============

Schizophrenia is a severe mental disorder with a lifetime morbid risk of approximately 1% across the world ([@B76]). Continuous treatment with sufficient dosage of antipsychotic drugs is essential in the therapy and management of schizophrenia ([@B38]). Second-generation antipsychotics \[also called atypical antipsychotic drugs (AAPDs)\] are first-line antipsychotics with greater improvement of negative symptoms and fewer extrapyramidal symptoms than first-generation antipsychotics. However, metabolic side effects (e.g., weight gain, dyslipidemia, hyperglycemia, etc.) induced by AAPDs raise the risk of cardiovascular diseases, which results in patient noncompliance, relapse, and increased mortality ([@B82]; [@B80]; [@B101]). Several studies have reported that antipsychotic-induced weight gain is reversible among pediatric and adult patients who discontinued treatment of antipsychotics ([@B29]; [@B127]). It is usually uneasy to make an optimum choice since benefits of these drugs have to be weighed against risks.

Although there have been tremendous reports on the metabolic side effects of atypical antipsychotic drugs, the mechanisms remain elusive ([@B98]). Available evidence has suggested that the clinical responses to antipsychotics and related side effects could vary from patient to patient. The large variability can be attributed to a variety of complex factors, in which genetic factors may play a dominant role. Numerous studies on pharmacogenomics have been conducted to elucidate gene variants related to antipsychotic-induced weight gain or metabolic disturbances ([@B67]; [@B151]; [@B147]). A meta-analysis has revealed that the genes of pharmacodynamic targets of antipsychotics like *HTR2C*, *DRD2*, *ADRA2A* and genes implicated in obesity such as *MC4R*, *GNB3*, *FTO*, *LEP*, *LEPR*, *BDNF*, and *INSIG2* seem to be consistently relevant to antipsychotic-induced weight gain ([@B151]). The current systematic review aims to provide an update on the gene polymorphisms related to lipid disturbances of AAPDs and to find the possible relations between central and peripheral pathways.

Methods {#s2}
=======

Literature research was conducted on PubMed (last: 31 October 2019) with the combinations of the key words: antipsychotic\* neuroleptic\*, gene, pharmacogen\*, polymorphism, weight gain, metabolic, and dyslipidemia. Inclusion criteria were: 1) patients with mental illness; 2) under the treatment of atypical antipsychotic drugs; 3) specific gene polymorphisms were studied; 4) outcomes involved in lipid metabolism such weight, BMI, and percentage of metabolic syndrome, etc. Exclusion criteria were: 1) a review or letter; 2) studies on animals; 3) studies of genes not examined in other studies. Totally, 43 studies were selected for this review (see [**Figure 1**](#f1){ref-type="fig"} and [**Table 1**](#T1){ref-type="table"} for details).

![Flowchart of study selection.](fphar-10-01669-g001){#f1}

###### 

Demographic, treatment, and lipid parameters of mentioned studies.

  Reference   Genes (SNPs)                       Functional SNPs   Risk allele   Period                  APs (n)                                                                                \% Caucasian                    Sample size (M/F), %FEDN     Age             Diagnoses                                        Single/multi-center   Lipid parameters
  ----------- ---------------------------------- ----------------- ------------- ----------------------- -------------------------------------------------------------------------------------- ------------------------------- ---------------------------- --------------- ------------------------------------------------ --------------------- ----------------------------------------------------------------------------------------------------
  [@B99]      *HTR2C* rs3813929 (-759C/T)        Yes               C             6, 10 wk                CP (69), RIS (46), CLO (4), FLU (3), SUL (1)                                           0 (100% Asian)                  123 (61/62), 100%            26.6 ± 7.7      SCZ                                              Single                BMI change, \>7% weight gain
  [@B120]     *HTR2C* rs3813929                  --                C             6 wk, 3 mo, 9 mo        RIS (26), OLZ (19), HAL (10), QUE (11), ZIP (6), AMI (1)                               100                             73 (55/18), 100%             25.2 ± 0.78     Psychosis                                        Single                BMI change, \>7% BMI increase
              *LEP* rs7799039 (-2548A/G)         Yes               G                                                                                                                                                                                                                                                                                
  [@B108]     *HTR2C* rs3813929                  --                C             4 wk                    RIS (53), OLZ (12), AMI (5), QUE (4), SGAs (10)                                        0 (100% Asian)                  84 (39/45), 69%              30.1 ± 7.4      SCZ                                              Single                \>5, \>7% BMI increase
  [@B83]      *HTR2C* rs3813929                  --                NS            Cross-sectional study   CLO, OLZ, RIS (\> 80%); others                                                         88                              112 (74/38), 0%              36 ± 10         SCZ (63%), SZA (25%), others (12%)               Single                Presence of MS, HDL-C, TG, Waist, BP
              *HTR2C* rs518147 (-697G/C)         Yes               C                                                                                                                                                                                                                                                                                
  [@B60]      *HTR2C* rs3813929                  --                NS            4 mo                    OLZ (61), RIS (47)                                                                     100                             108 (0/108), 89%             30.6 ± 11.5     SCZ, SZA                                         Two sites             ≥7% weight gain
  [@B114]     *HTR2C* rs3813929                  --                NS            6 wk                    CLO or OLZ (130), others                                                               68                              205 (141/64), N/A            35.9 ± 10.1     SCZ, SZA                                         Multiple              \>7% weight gain, % weight change
              *HTR2C* rs518147                   --                G                                                                                                                                                                                                                                                                                
              *HTR2C* rs6318 (Ser23Cys)          Yes               NS                                                                                                                                                                                                                                                                               
  [@B61]      *HTR2C* rs3813929                  --                T             3 mo                    OLZ (61), RIS (40)                                                                     100                             101 (0/101), 100%            33.47 ± 10.62   SCZ (76%), SZA (7%), delusional disorder (17%)   Single                FBG, TC, LDL, HDL, TG, BP, Waist, Hip; occurrence of MS
  [@B52]      *DRD2* rs4436578                   N/A               C             48.2 ± 27.8 mo          CLO (239), OLZ (70), RIS (170)                                                         0 (100% Asian)                  479 (292/187), 0%            47.2 ± 13.2     SCZ                                              Single                ≥7% weight gain
  [@B66]      *DRD2* rs1799732 (-141C Ins/Del)   Yes               Del           6 wk                    RIS (32), OLZ (26)                                                                     28 (40% African-American)       58 (44/14), 100%             23.5 ± 4.9      SCZ                                              Two sites             The log of the ratio of weight relative to baseline weight
  [@B84]      *DRD2* rs6277 (-957C/T)            N/A               C             6, 14 wk                CLO or OLZ (132), others                                                               62 (28% African American)       206 (141/65), N/A            35.69 ± 19.55   SCZ, SZA                                         Three sites           ≥7% weight gain, % weight change
              *DRD2* rs1079598                   N/A               C                                                                                                                                                                                                                                                                                
              *DRD2* rs1800497 (TaqIA)           N/A               A1 (T)                                                                                                                                                                                                                                                                           
  [@B126]     *DRD2* rs1799732                   --                NS            12 wk                   ZIP (59), OLZ (82), perazine (60)                                                      100                             191 (89/102), N/A            36.1 ± 12.4     SCZ                                              Two sites             Average weight change
              *DRD2* rs1800497                   --                NS                                                                                                                                                                                                                                                                               
  [@B2]       *DRD2* rs1799732                   --                NS            4 wk                    RIS                                                                                    100% South Indian               289 (175/114), N/A           35.3 ± 10.0     SCZ                                              Single                \>5% weight gain
              *HTR2C* rs3813929                  --                NS                                                                                                                                                                                                                                                                               
  [@B30]      *NPY* rs1468271                    N/A               G             Cross-sectional study   OLZ, QUE, or CP (165); others (192)                                                    88                              357 (229/128), 0%            37.6 ± 10.6     Severe mental illnesses                          Three sites           Serum glucose, TC, HDL-C, TG
  [@B123]     *NPY* rs10551063                   N/A               NS            7.03 ± 3.4 wk           CLO (99), HAL (18), OLZ (37), RIS (40), others (32)                                    70 (25% African American)       226 (151/75), 58%            35.78 ± 10.6    SCZ, SZA                                         Three sites           ≥7% weight gain, % weight change
              *NPY* rs16147                      Yes               C                                                                                                                                                                                                                                                                                
              *NPY* rs5573                       Yes               A                                                                                                                                                                                                                                                                                
              *NPY* rs5574                       Yes               T                                                                                                                                                                                                                                                                                
              *NPY* rs16475                      Yes               NS                                                                                                                                                                                                                                                                               
  [@B74]      *MC4R* rs489693                    N/A               A             12 wk                   RIS (84), QUE (25), ARI (30)                                                           55.4 (23.0% African American)   139 (81/58), 100%            13.38 ± 3.75    Various diagnoses (5% SCZ)                       Multiple              BMI change, weight change, fat mass, TG, TC, HDL-C, LDL-C, glucose, insulin, HOMA-IR index, leptin
                                                                                 6 wk                    CLO                                                                                    70                              73 (45/28), 0%               33.48 ± 8.33    SCZ                                                                    
                                                                                 6 wk                    RIS (20), QUE (5), ARI (15)                                                            100                             40 (22/18), 0%               35.20 ± 11.33   SCZ, SZA                                                               
                                                                                 12 wk                   HAL (31), AMI (21), QUE (25), ZIP (15)                                                 100                             92 (53/39), 100%             26.02 ± 5.17    SCZ, SZA, SZP                                                          
  [@B27]      *MC4R* rs17782313                  N/A               C             4 wk                    OLZ (135), CLO, RIS, PAL, QUE, AMI                                                     100                             345 (138/207), 26%           40.1 ± 14.7     Various diagnoses                                Single                \% weight gain, % BMI increase
  [@B28]      *MC4R* rs489693                    --                A             4 wk                    OLZ (135), CLO, RIS, PAL, QUE, AMI                                                     100                             341 (143/198), 25%           41.3 ± 15.0     Various diagnoses                                Single                \% weight gain, % BMI increase
  [@B23]      *MC4R* rs17782313                  --                NS            6-14 wk                 CLO (99), HAL (16), OLZ (36), RIS (40), others (33)                                    70 (25% African American)       224 (150/74), N/A            35.63 ± 10.50   SCZ, SZA                                         Three sites           \% weight gain
              *MC4R* rs11872992                  N/A               NS                                                                                                                                                                                                                                                                               
              *MC4R* rs8087522                   N/A               A                                                                                                                                                                                                                                                                                
  [@B153]     *MC4R* rs489693                    --                A             6 wk                    ZIP (330), ARI (313), OLZ (341), QUE (332), RIS (344), HAL (166), perphenazine (165)   0 (100% Asian)                  1991 (999/992), 28%          31.95 ± 7.93    SCZ                                              Multiple              \>7% BMI gain, % change of BMI, Waist, glucose, TG, HDL, LDL
              *MC4R* rs17782313                  --                NS                                                                                                                                                                                                                                                                               
  [@B149]     *BDNF* rs6265 (Val66Met)           Yes               Met           18 ± 6 y                CLO (98), RIS (36), FGAs (62)                                                          0 (100% Asian)                  196 (130/66) patients, 0%    N/A             SCZ                                              Single                BMI gain
                                                                                                                                                                                                                                50 (34/16) controls          N/A                                                                                    
  [@B125]     *BDNF* rs6265                      --                NS            49.2 ± 28.2 mo          CLO (266), OLZ (79), RIS (136)                                                         0 (100% Asian)                  481 (293/188), 0%            43.9 ± 8.9      SCZ                                              Single                \% weight gain
              *BDNF* rs11030101                  N/A               T                                                                                                                                                                                                                                                                                
              *BDNF* rs12291186                  N/A               NS                                                                                                                                                                                                                                                                               
  [@B146]     *BDNF* rs6265                      --                NS            6 wk                    CLO or OLZ (207); others                                                               100                             257 (188/69), 0%             31.8 ± 7.9      SCZ, SZA                                         Multiple              ≥7% weight gain
              *BDNF* rs1519480                   N/A               A                                                                                                                                                                                                                                                                                
  [@B150]     *BDNF* rs6265                      --                Met           Cross-sectional study   CLO                                                                                    0 (100% Asian)                  199 (143/56), 0%             55.3 ± 6.9      SCZ                                              Single                Presence of MS, individual parameters
  [@B44]      *BDNF* rs6265                      --                Val           7.26 ± 3.5              CLO (87), OLZ (32), RIS (31), HAL (15), others                                         68 (27% African American)       188 (126/62), 0%             35.8 ± 10.0     SCZ, SZA                                         Three sites           ≥7% weight gain, % weight change
  [@B40]      *BDNF* rs6265                      --                Met           Cross-sectional study   CLO (156), RIS (86), SGAs (66)                                                         0 (100% Asian)                  308 (205/103) patients, 0%   44.6 ± 10.3     SCZ                                              Single                BMI
                                                                                                         304 (180/124) controls                                                                 44.5 ± 14.4                                                                                                                                         
  [@B121]     *CNR1* rs806378                    N/A               T             7.54 ± 3.55 wk          CLO (101), OLZ (34), HAL (12), RIS (36)                                                64 (30% African-American)       183 (124/59), 0%             36.12 ± 10.17   SCZ, SCA                                         Three sites           \% weight gain
  [@B81]      *CNR1* rs1049353 (-1359G/A)        N/A               NS            24 wk                   CLO (25), OLZ (22), RIS (14), QUE (6), ARI (6), HAL (10)                               100                             83 (50/33) patients, 0%      44.0 ± 10.5     SCZ (86%)                                        Two sites             \>7% weight gain
                                                                                                                                                                                                80 (40/40) controls             49.4 ± 12.9                                                                                                         
  [@B94]      *CNR1* rs1049353                   --                NS            Over 1 y                OLZ                                                                                    0 (100% Asian)                  78 (52/26), N/A              46.4 ± 11.6     SCZ                                              Three sites           ≥7% weight gain
              *CNR1* rs806368                    --                NS                                                                                                                                                                                                                                                                               
              *CNR1* rs4707436                   N/A               NS                                                                                                                                                                                                                                                                               
  [@B145]     *CNR1* rs6928499                   N/A               G             Cross-sectional study   CLO or OLZ (197); others                                                               95.1                            407 (274/133), 0%            35.6 ± 11.0     SCZ (69.3%), SZA (20.1%), SZP (10.6%)            Single                Presence of MS, individual parameters
              *CNR1* rs1535255                   N/A               T                                                                                                                                                                                                                                                                                
              *CNR1* rs2023239                   N/A               T                                                                                                                                                                                                                                                                                
  [@B58]      *LEP* rs7799039 (-2548A/G)         Yes               A             453 ± 289 d             OLZ                                                                                    0 (100% Asian)                  74 (50/24), N/A              47.2 ± 11.6     SCZ                                              Three sites           ≥7% weight gain
  [@B144]     *LEP* rs7799039                    --                G             Cross-sectional study   CLO (21), OLZ (31), RIS (16)                                                           100                             134 (87/47), 0%              41.6 ± 11.8     SCZ, SZA                                         Two sites             Presence of MS, Waist, BMI, BMI ≥30 kg/m^2^, presence of central obesity
              *HTR2C* rs3813929 (-759C/T)        --                NS                                                                                                                                                                                                                                                                               
  [@B46]      *LEP* rs7799039                    --                A             Cross-sectional study   OLZ (99), CLO (86), QUE (56), RIS (46), ARI (14)                                       100                             353 (184/169), 0%            N/A             Psychotic disorder (50.7%)                       Single                Serum TC/HDL
  [@B47]      *LEP* rs7799039                    --                NS            within 1 y              CLO (68), OLZ (54), QUE (31), ARI (23), RIS (30)                                       100                             141 (82/59), 0%              N/A             Psychotic disorder (63.1%)                       Single                BMI \>30, BMI change, BMI change per week
  [@B16]      *LEP* rs7799039                    --                NS            7.19 ± 3.47 wk          CLO (80), OLZ (28), RIS (32), HAL (16), others (24)                                    70.2 (23.8% African-American)   181 (118/63), N/A            35.93 ± 10.94   SCZ, SZA                                         Three sites           \% weight change
              *LEP* rs10954173                   N/A               NS                                                                                                                                                                                                                                                                               
              *LEP* rs3828942                    N/A               NS                                                                                                                                                                                                                                                                               
  [@B65]      *INSIG2* rs17587100                N/A               N/A           12 ± 1.2 wk             CLO                                                                                    100                             160 (97/63), 0%              21.9 ± 8.9      Schizophrenia spectrum disorders                 Single                BMI change
              *INSIG2* rs10490624                N/A               N/A                                                                                                                                                                                                                                                                              
              *INSIG2* rs17047764                N/A               N/A                                                                                                                                                                                                                                                                              
  [@B89]      *INSIG2* rs17587100                --                NS            6 wk                    CLO, OLZ, RIS, AMI, QUE, SGAs                                                          100                             128 (48/80), 17%             38.63 ± 11.96   SCZ, SZA                                         Three sites           ≥7% weight gain, % weight change
              *INSIG2* rs10490624                --                NS                                                                                                                                                                                                                                                                               
              *INSIG2* rs17047764                --                NS                                                                                                                                                                                                                                                                               
  [@B122]     *INSIG2* rs17587100                --                NS            7.94 ± 3.74 wk          CLO (96), OLZ (34), RIS (12), HAL (12)                                                 57.8 (35.1% African-American)   154 (110/44), 0%             35.78 ± 9.82    SCZ, SZA                                         Three sites           ≥7% weight gain, % weight change
              *INSIG2* rs10490624                --                NS                                                                                                                                                                                                                                                                               
              *INSIG2* rs17047764                --                NS                                                                                                                                                                                                                                                                               
  [@B68]      *INSIG2* rs11123469                N/A               C             Cross-sectional study   CLO (171), OLZ (91), RIS (194)                                                         0 (100% Asian)                  456 (369/157), 0%            N/A             SCZ                                              Single                Prevalence of MS
              *INSIG2* rs10185316                N/A               NS                                                                                                                                                                                                                                                                               
              *INSIG2* rs1559509                 N/A               NS                                                                                                                                                                                                                                                                               
  [@B135]     *ADRA2A* rs1800544 (-1291C/G)                        G             14.0 ± 6.2 mo           CLO                                                                                    0 (100% Asian)                  93 (49/44), 0%               38.4 ± 8.1      SCZ                                              Single                Weight gain, \>7% weight gain
  [@B92]      *ADRA2A* rs1800544                 --                G             Over 1 y                OLZ                                                                                    0 (100% Asian)                  62 (44/18), 0%               46.5 ± 11.1     SCZ                                              Two sites             \>10% weight gain, % weight change
  [@B115]     *ADRA2A* rs1800544                 --                C             8.4 ± 3.6 wk            CLO (85), OLZ (20), RIS (13), HAL (11)                                                 50 (42% African-American)       129 (96/33), 0%              36.5 ± 9.0      SCZ, SZA                                         Multiple              weight gain, % weight change
  [@B102]     *ADRA2A* rs1800544                 --                NS            Cross-sectional study   OLZ (106), RIS (103), CLO (102), ARI (21), QUE (12), SGAs (69)                         94                              470 (320/150), 0%            38 ± 10         SCZ (78%), SZA (17%)                             Multiple              Presence of MS, HDL, TC, Waist, BP, glucose
  [@B31]      *ADRA2A* rs1800544                 --                NS            8.3 ± 3.7 wk            CLO (91), OLZ (22), HAL (12), RIS (14)                                                 51.8 (40.3% African-American    139 (101/38), N/A            36.2 ± 9.4      SCZ                                              Three sites           \% weight change, weight gain \>8%

SCZ, schizophrenia; SZA, schizoaffective disorder; SZP, schizophreniform disorder; FEDN, first-episode drug-naïve patients; SNPs, single nucleotide polymorphisms; N/A, not available; NS, not significant; APs, antipsychotics; FGAs, first-generation antipsychotics; FLU, fluphenazine; HAL, haloperidol; CP, chlorpromazine; CLO, clozapine; OLZ, olanzapine; RIS, risperidone; ARI, aripiprazole; QUE, quetiapine; AMI, amisulpride; ZIP, ziprasidone; PAL, paliperidone; SUL, sulpiride; d, days; wk, weeks; mo, months; y, years; M, male; F, female; MS, metabolic syndrome; HDL, high-density lipoprotein; HDL-C, HDL cholesterol; LDL, low-density lipoprotein; LDL-C, LDL cholesterol; FBG, fasting blood glucose; BP, blood pressure; TG, triglycerides; TC, total cholesterol; HOMA-IR index, the homeostasis model assessment insulin resistance index; Waist, waist circumference; Hip, hip circumference.

Gene Polymorphisms Related to Central Nervous System {#s3}
====================================================

The Serotonin 5-HT~2c~ Receptor {#s3_1}
-------------------------------

Central serotonin system is associated with the modulation of feeding behavior ([@B63]). There are at least seven subtypes of 5-HT receptors, of which the 5-HT~2~ subtype is divided into 5-HT~2A~, 5-HT~2B~, and 5-HT~2C~. The serotonin 5-HT~2C~ receptor has shown the most consistent findings in studies on atypical antipsychotic drug-induced lipid disturbances. The serotonin 5-HT~2C~ receptor is present in hypothalamic nuclei such as the arcuate nucleus (ARC) and the ventral tegmental area (VTA) ([@B41]). Animal experiments have shown that 5-HT~2C~ receptor agonists reduce feeding ([@B24]), and the antagonists increase feeding and lead to weight gain ([@B13]). The serotonin 5-HT~2C~ receptor gene knockout mice ate more than the controls and became obesity ([@B119]). Numerous studies have indicated that 5-HT~2C~ receptor mediates leptin-induced anorexia, but reports regarding serotonin-leptin interactions are discrepant ([@B134]; [@B132]; [@B138]). Cannabinoid receptor 1 (CB~1~ receptor) stimulation could inhibit the secretion of cerebral serotonin in the mouse brain ([@B86]). Coupled with the inhibition of neuropeptide Y (NPY)/agouti-related protein (AgRP) neurons by 5-HT~1B~ receptor action, 5-HT~2C~ receptor mediates the activation of pro-opiomelanocortin (POMC) neurons as a downstream pathway of serotonin controlling food intake ([@B63]). Showing the highest antagonizing affinity to 5-HT~2C~ receptor among antipsychotic drugs, clozapine and olanzapine exert the most serious effects of weight gain in patients ([@B3]). It suggested that the antagonism against 5-HT~2C~ receptor by antipsychotic drugs may lead to increased food intake and eventually weight gain. This is supported by the observation that olanzapine exerts its metabolic side effects by targeting 5-HT~2C~ receptor in mouse model ([@B72]).

The promoter region of *HTR2C* gene is mainly influenced by -759C/T (rs3813929) and -697G/C (rs518147) polymorphisms. *HTR2C* -759C/T polymorphism was the first single nucleotide polymorphism (SNP) to be reported as an associated *HTR2C* polymorphism with antipsychotic drug-induced weight gain ([@B99]). Besides, it is the most replicated gene polymorphism related to AAPD-induced weight gain ([@B151]). Various clinical studies suggested that *HTR2C* -759C allele was a risk allele of a substantial weight gain (over 7% than baseline) in patients treated with typical or atypical antipsychotic drugs ([@B99]; [@B120]; [@B108]). A study in first episode drug-naive female patients with schizophrenia showed that -759T is associated with an increase in waist circumference, fasting blood glucose, and blood triglyceride levels ([@B61]). However, associations between *HTR2C* -759C/T polymorphism and weight gain or presence of metabolic syndrome were reported to be nonsignificant in other studies ([@B83]; [@B60]; [@B114]; [@B2]). Despite the negative results, haplotype analyses suggested that *HTR2C* 759C-697G-Cys23 haplotype was associated with the most percentage weight gain induced by various antipsychotics ([@B114]).

Dopamine Receptor D2 {#s3_2}
--------------------

Dopamine receptor D2 (DRD2) is the main target of antipsychotic drugs. An animal study found that the availability of striatal D2 receptor in obese rats was lower than that in lean controls ([@B50]). In a human study, the striatal dopamine transporter availability was negatively correlated with body mass index (BMI) in a group of healthy volunteers ([@B19]). It is postulated that it could be a mechanism of overeating that the neuropeptides regulating homeostatic energy balance also modulate the activity of dopamine neurons and the rewarding circuits underlying food intake ([@B133]). Therefore, Blum et al. hypothesized that as dopamine D2 receptor antagonists, antipsychotic drugs cause a hypodopaminergic reward circuitry, leading to excessive food intake and ultimately obesity ([@B12]). Functional magnetic resonance imaging (fMRI) showed that an increased activity in striatal regions of the reward system was positively correlated with weight gain after 6-week amisulpride treatment ([@B87]).

The role of *DRD2* rs4436578-C in weight gain induced by atypical antipsychotics is verified in 479 chronic schizophrenic patients under long-term treatment of clozapine, olanzapine, or risperidone ([@B52]). *DRD2* promoter region polymorphism -141C Ins/Del (rs1799732) was also reported to be associated with weight gain in 58 first episode patients treated with randomly-assigned olanzapine or risperidone for 6 weeks ([@B66]), whereas nonsignificant associations were found in later studies of larger samples ([@B126]; [@B2]). A systematic analysis of genetic polymorphisms spanning the five dopamine receptor genes (*DRD1*--*DRD5*) found only *DRD2* rs6277 (C957T), rs1079598, and rs1800497 (TaqIA) to be significantly associated with antipsychotic-induced weight gain in chronic patients with schizophrenia or schizoaffective disorder ([@B84]). It was suggested that the C957T polymorphism would not change the amino acid sequence of the dopamine D2 receptor, but it was related to the stability of the striatum D2 receptor ([@B51]) and the stability and half-life of the *DRD2* messenger RNA (mRNA) ([@B35]). The TaqIA polymorphism is located in coding region of the adjacent *ANKK1* gene and overlaps with the 3' end region of the *DRD2* gene. So, it may be in linkage disequilibrium with a functional polymorphism of *DRD2*, or may affect the dopamine signaling through the *ANKK1* gene. Studies have shown that if the TaqIA site is A1, it may result in decreased expression of *DRD2* and decreased dopaminergic activity ([@B45]).

Neuropeptide Y {#s3_3}
--------------

NPY is a 36-amino-acid peptide expressed in the central and peripheral nervous system. In the ARC neurons, NPY colocalizes with AgRP, which can antagonize α-melanocyte-stimulating hormones (α-MSH) binding to melanocortin-3 receptor (MC3R) and melanocortin-4 receptor (MC4R). Another group of neurons co-express POMC and cocaine and amphetamine-regulated transcript (CART) and inhibit food intake ([@B5]). Low leptin levels can upregulate neuropeptide Y and exert orexigenic effects. Leptin directly and differentially regulates NPY and POMC neurons, and then controls feeding behavior and energy homeostasis ([@B37]). Outside the hypothalamus, NPY mainly exists in the brainstem and the catecholaminergic neurons in the sympathetic nervous system. Results *in vitro* indicate that NPY may inhibit lipolysis in murine adipocytes ([@B15]). Transgenic mice overexpressing NPY showed significant obesity and the lipogenic effects as well as inhibition of catecholaminergic tone of NPY were suggested ([@B129]). NPY and leptin are recognized to interact in a homeostatic loop to regulate energy balance not only in the brain, but also directly at the adipocyte level ([@B75]).

Chronic treatment of atypical antipsychotic drugs increased NPY immunoreactivity and mRNA expression in the rat hypothalamus ([@B59]; [@B137]). *NPY* rs1468271 was associated with hypercholesterolemia in patients taking olanzapine, quetiapine, or chlorpromazine ([@B30]). Significant associations between the SNPs rs16147, rs5573, and rs5574 in *NPY* and weight gain in clozapine or olanzapine-treated patients of European ancestry were reported ([@B123]). Compared with carriers of TT genotype at rs16147, individuals with the C allele showed a higher risk of weight gain probably due to increased NPY levels. Besides, genetic interaction between rs16147 in *NPY* and rs806378 in cannabinoid receptor 1 gene further supports their biological interaction ([@B123]).

The Melanocortin 4 Receptor {#s3_4}
---------------------------

The MC4R is a transmembrane G protein-coupled receptor expressed in the hypothalamus and peripheral tissues. The central melanocortin system potently regulates feeding and directly controls lipid metabolism in liver and adipocytes ([@B88]). MC4R plays a key role in suppressing food intake. *MC4R* gene is the most common single-gene effect of human obesity ([@B9]). Rodent experiments showed that *Mc4r* knockout mouse exhibited hyperinsulinemia, hyperglycemia, and adult obesity syndrome ([@B118]). Multiple pathways are involved in the regulation of central melanocortin system in energy homeostasis ([@B113]). MC4R signaling regulates energy balance through stimulating brain-derived neurotrophic factor (BDNF) expression in the ventromedial hypothalamus (VMH) ([@B142]). Central melanocortin pathway through MC4R is an indispensable downstream mediator of the anorexigenic effect of serotonin ([@B62]). The expression of MC4R in the rat hypothalamus is increased under the long-term treatment of antipsychotics probably through a compensatory mechanism ([@B103]). A genome-wide association study found that *MC4R* rs489693 demonstrated consistent effects on weight gain, as well as on levels of triglycerides, leptin, and insulin, HOMA-IR index (the homeostasis model assessment insulin resistance index), and total fat mass ([@B74]). Afterward, the association between *MC4R* rs489693 A-allele and greater weight gain was confirmed ([@B28]). They also reported carriers of *MC4R* rs17782313 C-allele at risk of greater percentage weight gain after taking atypical antipsychotics ([@B27]). However, Chowdhury et al. didn't replicate the significant association of rs17782313, but they reported that carriers of rs8087522-A gained significantly more weight than non-carriers in white Americans ([@B23]). Located in the *MC4R* promoter region, rs8087522 A-allele may affect the gene expression of *MC4R* by binding to an unknown nuclear protein, while the G-allele has no effect. A large-scale pharmacogenetic study in Chinese schizophrenia patients reported the ubiquitous association between rs489693 and metabolic measures, while rs17782313 is less involved in antipsychotic-induced metabolic disturbances ([@B153]).

Brain-Derived Neurotrophic Factor {#s3_5}
---------------------------------

The BDNF is a member of the neurotrophic factor family abundantly expressed in the hippocampus and hypothalamus. Beyond a fundamental role in the brain development and plasticity, BDNF is thought to play a major part in the regulation of food intake ([@B104]). It is reported that central infusion of BDNF can induce dose-dependent food restriction and weight loss, perhaps *via* its up-regulation of hypothalamic serotonin activity ([@B95]). BDNF was also observed to regulate food intake *via* its inhibitory effect on NPY and modulation of the dopamine system ([@B136]; [@B25]). Researchers have found reduced serum BDNF levels in first-episode drug naive psychosis patients and a trend of greater reductions in female patients ([@B57]). Moreover, a significant increase in BDNF levels in prefrontal cortex and cerebrospinal fluid samples of postmortem schizophrenia patients was reported ([@B55]). Thus, alterations in BDNF may play a role in the pathophysiology of schizophrenia ([@B42]). Both typical (haloperidol) and atypical antipsychotic drugs (clozapine, risperidone) decrease serum BDNF levels in schizophrenia patients ([@B141]) and the expression of *Bdnf* mRNA in the hippocampus of rats ([@B4]; [@B69]; [@B22]) although results are inconsistent in some studies ([@B6]; [@B93]). Further, reduced serum BDNF levels may be related with weight gain in female but not in male patients with schizophrenia under long-term antipsychotic treatment ([@B148]). The effect of BDNF on weight gain induced by antipsychotics seems to be gender-specific but the results are inconsistent.

Human *BDNF* gene is located on chromosome 11p14.1. The Val66Met variant (rs6265) in the *BDNF* promoter region is the most investigated SNP of the gene, showing an association of cognitive impairment ([@B8]) and obesity ([@B117]). It markedly alters the intracellular trafficking and packaging of pro-BDNF and impacts the activity-dependent secretion of the mature peptide ([@B36]). The Met/Met genotype of the *BDNF* Val66Met polymorphism has a significant effect on BMI gain and metabolic syndrome in male but not female schizophrenic patients treated with long-term antipsychotic drugs ([@B149]; [@B150]; [@B40]). However, these results are incompatible with some studies that indicate Val/Val was associated with greater weight gain induced by antipsychotics ([@B44]). Tsai et al. failed to replicate the relationship between the Val66Met polymorphism and body weight gain after long-term antipsychotic treatment, but they found a visible difference in percentage weight change in patients with different copies of haplotype GTA (rs6265-rs11030101-rs12291186) ([@B125]). Additionally, a two-marker haplotype rs6265-rs1519480 was also reported to be associated with antipsychotic-induced weight change in European ancestry ([@B146]).

The Cannabinoid 1 Receptor {#s3_6}
--------------------------

The endocannabinoid system is involved in modulating energy homeostasis by controlling food intake *via* central and peripheral pathways, as well as stimulating lipogenesis and fat accumulation ([@B33]; [@B11]). It may be negatively regulated by leptin in the neural circuitry ([@B34]). In the hypothalamus, the interaction between the endocannabinoid and NPY systems appears to be bidirectional, and peripheral endocannabinoid levels are increased in obese mice induced by neuropeptide Y overexpression ([@B128]). Encoding by the gene *CNR1*, the CB~1~ receptor mediates the effects of cannabinoid binding primarily in the brain and also presents in peripheral tissues, including adipocytes ([@B10]), hepatocytes ([@B90]), pancreas ([@B85]), muscle ([@B79]), and the gut ([@B26]). *Cnr1* knockout mice experienced food restriction compared with wild-type littermates ([@B34]). Selective CB~1~ receptor antagonist SR141716A (rimonabant) ameliorates diet-induced obesity of mice through enhancement of fatty acid oxidation and energy expenditure in white adipocytes ([@B56]), or modulating macrophage inflammatory mediators *via* gut microbiota alterations ([@B78]). Clinical trials proved that rimonabant decreased body weight and waist circumference in overweight or obese patients ([@B130]; [@B96]). The 3813G allele at the exon 4 of *CNR1* is associated with obesity-related phenotypes like waist circumference and subscapular skinfold thickness in adult men ([@B107]).

Evidence from pre-clinical, clinical, genetic, postmortem, and neuroimaging studies have indicated an important role of the endocannabinoid system and cannabinoid receptors in the pathophysiology of schizophrenia ([@B39]). The G allele frequency of the *CNR1* 1359G/A gene polymorphism potentially relates to therapeutic response to atypical antipsychotics ([@B49]). Alterations in CB~1~ receptor-mediated G-protein signaling by antipsychotic treatment was different in a sex- and age-selective manner ([@B139]). Chronic treatment with aripiprazole upregulated the gene expression of *Cnr1* in the frontal cortex of rats ([@B21]). Risperidone increased CB~1~ receptor binding in rat brain ([@B111]). Oral intake of haloperidol or olanzapine produces region-specific increase in cannabinoid receptor levels distinctly ([@B32]). Both CB~1~ receptor antagonist NESS06SM and inverse agonist rimonabant reduced food intake and weight gain and restored all blood parameters in a rat model treated with olanzapine ([@B64]). However, the results of the relationship between *CNR1* polymorphisms and antipsychotic-induced lipid disturbances differ from various single nucleotide polymorphisms. A study of 20 tag SNPs found the rs806378 polymorphism to be associated with weight gain in European patients treated with clozapine or olanzapine ([@B121]). *CNR1* polymorphisms -1359 G/A (rs1049353, rs806368, and rs4707436) were not associated with antipsychotic-induced weight gain ([@B81]; [@B94]). A cross-sectional study of a naturalistic cohort of 407 patients with schizophrenia showed the minor alleles of rs6928499, rs1535255, and rs2023239 were associated with lower levels of high-density lipoprotein cholesterol and fasting glucose ([@B145]).

Gene Polymorphisms Related to Peripheral Tissues {#s4}
================================================

Leptin {#s4_1}
------

Leptin is a peptide hormone predominantly secreted by adipocytes, targeting hypothalamic nerve network to suppress appetite. At peripheral level, leptin is involved in the regulation of lipid and glucose metabolism in adipose tissue, liver, and skeletal muscle, as well as gastrointestinal nutrient absorption ([@B109]). Leptin resistance primarily takes responsibility for obesity in some studies ([@B109]). Serum leptin levels were elevated significantly after treatment of olanzapine, clozapine, and quetiapine, whereas haloperidol and risperidone produced nonsignificant leptin changes ([@B97]). The significant association between leptin increases and BMI changes was observed across studies. Two hypotheses about the role played by leptin in antipsychotic-induced weight gain were proposed: leptin as an epiphenomenon of weight gain, or antipsychotic-induced leptin resistance causing weight gain ([@B91]).

Therefore, the correlation between leptin gene (*LEP*) and lipid disturbances induced by atypical antipsychotics has been a research hotspot. Among the polymorphisms, *LEP* rs7799039 (-2548A/G) was verified to be associated with weight gain in many studies ([@B120]; [@B58]; [@B112]). A cross-sectional study showed that serum total cholesterol (TC)/high-density lipoprotein (HDL) ratio in *LEP* -2548G male carriers was lower than that of non-carriers after taking AAPDs for more than 3 months, but not significant in female patients ([@B46]). However, a longitudinal study conducted by the same group found *LEP* -2548G was not significantly associated with BMI change during treatment of atypical antipsychotics ([@B47]). A haplotype of *LEP* rs7799039G-rs10954173G-rs3828942G showed a significant association with weight gain despite results of all the SNPs were not significant ([@B16]). A meta-analysis indicated that the *LEP* -2548A allele was associated with an increased risk of antipsychotic-induced weight gain in Asian patients, while it seemed to decrease the risk in European populations ([@B112]). Combined genotype analysis revealed that gene-gene interaction between the *LEP* and *HTR2C* polymorphisms was highly significant in their associations with occurrences of metabolic syndrome, BMI, and waist circumference ([@B144]).

Insulin-Induced Gene 2 {#s4_2}
----------------------

In the endoplasmic reticulum (ER), insulin-induced gene (INSIG) proteins form complexes with sterol-regulatory element-binding proteins (SREBPs) and SREBP cleavage activating proteins (SCAP), regulating cholesterol and lipid fatty acid biosynthesis ([@B77]). There are two isoforms of INSIG proteins, INSIG1 and INSIG2. INSIG2 is not a transcriptional target of SREBPs as INSIG1, but it can also cause the retention of the SCAP/SREBP complex in the ER in a sterol dependent way and thereby blocks cholesterol synthesis ([@B143]). The INSIG2/SCAP/SREBP signaling may be altered by various antipsychotic drugs. Both clozapine and haloperidol can activate the gene expressions of the SREBP system in human glioma cells, which may be a mechanism of therapeutic efficacy ([@B43]). But the upregulation of the lipogenesis in peripheral tissues can be a cause of the metabolic side effects induced by antipsychotics. Clozapine and risperidone significantly reduced INSIG2 and activated the expression of SCAP/SREBP in rat liver ([@B17]). It is reported that AAPD treatment induces early-stage lipid biosynthesis in adipose-derived stem cells (ASCs) and such abnormal lipogenesis can be reversed when INSIG2 expression was increased ([@B20]). Three markers (rs17587100, rs10490624, and rs17047764) localized within or near the *INSIG2* gene had a strong association with clozapine-induced BMI gain in German patients with schizophrenia ([@B65]). However, significant associations of the three aforementioned SNPs weren't replicated in other European patients ([@B89]; [@B122]). Liou et al. demonstrated that the C-C-C haplotype of *INSIG2* rs11123469-rs10185316-rs1559509 significantly elevated the risk of AAPD-induced metabolic syndrome ([@B68]). This association can be attributed to the action of *INSIG2* independently or the gene-gene interaction with *INSIG1*.

Adrenergic Alpha-2a Receptor {#s4_3}
----------------------------

The sympathetic nervous system regulated by the hypothalamus plays an important role in energy expenditure and lipolysis. Adrenergic α-2 receptors are classified into three subtypes, α~2A~, α~2B~, and α~2C~. Mice lacking α~2A~-adrenoceptors (ADRA2A) showed increased energy expenditure, lipolysis, and hyperinsulinemia ([@B106]). Atypical antipsychotics have affinities for adrenergic receptors, including subtypes of α~2A~, α~2B~, α~2C~, α~1A~, α~1B~ ([@B105]). The -1291 C/G promoter polymorphism (rs1800544) located in the regulatory promoter sequence of the *ADRA2A* gene may influence the transcription factor control. Association between *ADRA2A* rs1800544 polymorphism and schizophrenia was found in a study of Czech male patients with schizophrenia ([@B71]). Carriers of *ADRA2A* 1291-GG gained more weight than the subjects with genotype 1291-CC in Asian patients after long-term treatment of clozapine or olanzapine ([@B135]; [@B92]). But results of European-Americans showed the carriers of the *ADRA2A* -1291C allele gained more weight during treatment of 8.4 weeks on average ([@B115]). The association between *ADRA2A* -1291C/G and the prevalence of metabolic syndrome wasn't significant among white patients using antipsychotics ([@B102]). No significant association between *ADRA2A* -1291C/G and weight gain could be detected in another study among complex ethnic subjects treated with different antipsychotic drugs ([@B31]). Conflicting results might be attributed to ethnic differences and diverse observation periods.

Relations Between Genes in Central Nervous System and Peripheral Tissues {#s5}
========================================================================

Gene expression in central nervous system is not readily available, therefore, it is of great importance to find equivalent evidence from the peripheral blood. It was reported that gene expression in peripheral blood mononuclear cells could be used as a fingerprint of central nervous system disease ([@B1]). Thus, we focus on the network connections between the regulatory mechanisms of central nervous system pathways and peripheral pathways. The connection of the overall related genes mentioned in this review is shown in [**Figure 2**](#f2){ref-type="fig"}. It is obvious that antipsychotics might induce weight gain or metabolic syndrome through central and peripheral ways. In central nervous system, *HTR2C*, *DRD2*, *LEP*, *NPY*, *MC4R*, *BDNF*, *CNR1* polymorphisms play an important role in regulating food intake, and they can be affected by AAPDs. Besides, the lipid metabolism in peripheral tissues may be altered by the SNPs of *LEP*, *NPY*, *MC4R*, *CNR1*, *INSIG2*, and *ADRA2A*. As we can see in [**Figure 2**](#f2){ref-type="fig"}, complex pathways are involved in the modulation of energy intake and energy expenditure, that is orexigenic and anorexigenic mechanisms. NPY/AgRP neurons and POMC neurons play a fundamental role in the downstream of the pathway of *LEP*, *CNR1*, and *HTR2C*. *NPY* is an orexigenic mediator whereas *MC4R* exerts anorexigenic effects. *HTR2C* mediates the effects of multiple genes, such as *LEP*, *CNR1*, and *BDNF*. Dopamine regulates appetite mainly through brain reward circuits. Leptin is an upstream molecular bridging the peripheral tissue and central nervous system. Secreted from fat cells, leptin acts on the hypothalamus through the blood-brain barrier, and ultimately suppresses appetite by triggering multiple signaling cascades like *NPY*, *MC4R*, *CNR1*. In peripheral tissues, multiple hormones or peptides affect lipid metabolism, such as leptin, neuropeptide Y, melanocortin, endocannabinoids, insulin, and norepinephrine, etc. Inhibition of lipolysis and stimulation of lipogenesis lead to hyperlipemia and obesity.

![Gene-gene interaction among genes associated with atypical antipsychotic-induced lipid disturbances. The central and peripheral pathways are separated by brain-blood barrier, with leptin through it. Neuropeptide Y (NPY)/agouti-related protein (AgRP) neurons and pro-opiomelanocortin (POMC) neurons play a fundamental role in the downstream of the pathway of *LEP*, *CNR1*, and *HTR2C*. NPY is an orexigenic mediator whereas melanocortin-4 receptor (MC4R) exert anorexigenic effects. *HTR2C* mediates the effects of multiple genes, such as *LEP*, *CNR1*, and *BDNF*. Dopamine regulate appetite mainly through brain reward circuits. As a bridge between the central and peripheral ways, leptin inhibits food intake by triggering multiple signaling cascades like *NPY*, *MC4R*, *CNR1*. In peripheral tissues, multiple hormones or peptides modulating lipid metabolism, such as leptin, neuropeptide Y, melanocortin, endocannabinoids, insulin, and norepinephrine etc. Inhibition of lipolysis and stimulation of lipogenesis lead to hyperlipemia and obesity. The solid and dotted lines indicate upregulation and downregulation respectively. ↑: activated by AAPDs; ↓: inhibited by AAPDs; yellow arrows indicate compensatory effects rather than direct effects; NE, norepinephrine.](fphar-10-01669-g002){#f2}

Conclusion {#s6}
==========

Pharmacogenomics helps to find possible genetic polymorphisms related to lipid disturbances induced by atypical antipsychotic drugs and the variation among different patients. Nevertheless, inconsistency and limitations have impeded the progress in this field. As mentioned above, discrepancies often occur between different studies on the same SNP. Several reasons are to be noted. A small sample size may reduce the statistical power; and the representativeness of the sample can be weakened if the frequency of a certain base is low in a small sample. Ethnic, gender, and age differences should be taken into account. Evidence has shown worse lipid metabolic dysfunction in female schizophrenia patients due to antipsychotics ([@B18]). Sex differences were also found in gene expression associated with antipsychotic induced weight gain ([@B110]). Younger age has been reported to be a risk of greater antipsychotic-related weight gain ([@B73]; [@B48]). The degree of the metabolic side effects varies from antipsychotics and doses. Evidence suggested a dose-dependent effect between serum levels and metabolic side effects of clozapine and olanzapine although the relationship between daily dose and metabolic disturbances is not clear. ([@B116]). First episode drug-naive patients are more sensitive to the AAPDs than chronic ones, which may cause the distinct exposure to the adverse drug reaction. Long-term treatment and short-term treatment might be different in the effects of weight gain or metabolic syndrome. To observe the alteration of BMI, a long enough study duration makes it easier to get a significant result. For instance, *LEP* -2548A/G polymorphism showed nonsignificant association with short-term (6-week and 3-month) weight change but was associated with 9-month antipsychotic-induced weight gain ([@B120]). Meanwhile, although metabolic syndrome was verified to be related to weight gain for patients under the treatment of clozapine ([@B7]), different indicators (BMI or blood lipid levels, etc.) and diverse definitions can lead to inconsistency. Significant end points vary from body weight (or BMI) increase ≥7% of baseline to change of metabolic parameters or presence of metabolic syndrome. Hyperlipidemia (hypertriglyceridemia or hypercholesterolemia) may be the outcome of weight gain or a direct effect of antipsychotics. A rodent experiment found that only olanzapine significantly induced weight increase in rats, but both olanzapine and clozapine elevated blood lipid levels after 9-week treatment at clinic equivalent doses ([@B70]). Therefore, different outcome variables of lipid disturbances may be analyzed separately. As for animal studies, we should pay more attention to the different regions (the striatum, the hypothalamus, etc.) and species differences when we compare the various conclusions from a bulk of published work. For example, anatomical studies and physiological experiments have suggested significant interspecies differences in the distribution of the cannabinoid 1 receptor both in central and peripheral nervous system ([@B53]). Furthermore, since some genes participate in the metabolic side effects as well as the pharmaceutical effect, the functions of the AAPDs can be complex to analyze.

Genetic correlation study consists of single nucleotide polymorphisms, haplotype analysis, gene-gene interaction, genome wide association study (GWAS), etc. Several susceptibility gene loci have been reported but the exact mechanism hasn't been illuminated. Additionally, correlations do not imply causations. Hence, *in vitro* and *in vivo* studies are needed to explore the specific effects of AAPDs on these related genes and gene-gene interactions. Further functional analyses are also required to verify which are the functional polymorphisms and the specific functional consequences of these SNPs. Moreover, both obesity and schizophrenia are polygenic diseases, so we can speculate that the metabolic side effects of atypical antipsychotics cannot be monogenic. Research strategies of monogenic diseases are inapplicable to find out the complex causations currently. Given the limitations of such research, more efficient methods are in great need. The International Schizophrenia Consortium proposed a polygenic risk score (PRS) test for schizophrenia ([@B54]). Now schizophrenia polygenic risk score has been reported to be a potential predictor of antipsychotic efficacy in patients with first-episode psychosis (Jian-Ping [@B152]). In addition, the hypothesis of an omnigenic model proposed by Boyle et al. provide us with a new perspective to understand gene effects---core genes and peripheral genes. ([@B14]).

Future Perspective {#s7}
==================

Although the pharmacological mechanisms and pharmacogenomics of atypical antipsychotic drugs seem to be hard to figure out, research on weight gain and dyslipidemia induced by atypical antipsychotics is of great significance. On one hand, combining genetic markers and relevant clinical indicators, a pharmacogenetic model can be built to predict the risk of lipid disturbances for an individual patient using atypical antipsychotics. Consequently, it will allow clinicians to select appropriate medication with less metabolic side effects and enough efficacy for every patient and promote individualized treatment. A multigene risk-model has showed promising results of predicting antipsychotic-induced weight gain ([@B124]). Moreover, the combinatorial model of genetic and clinical data could help to identify patients at high risk for early weight gain ([@B131]). On the other hand, the more we know about the mechanism of the metabolic side effects of atypical antipsychotics, the better we can tackle with this troublesome adverse drug reaction. More specifically, maybe we can develop novel molecules with high receptor selectivity or new drug targets. And toxicities could be designed out by counter-screening approaches combined with medicinal chemistry methods when discovering selectively non-selective drugs representing highly effective treatments ([@B105]). Besides, combination with lipid-lowering medication might help to attenuate weight gain or dyslipidemia. Metformin is a good try. In a double-blind and placebo-controlled study, metformin addition showed great efficacy, safety, and good adherence in preventing olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients ([@B140]). In addition, recently a preclinical study indicates that the selective protein kinase C*β* (PKC*β*) inhibitor, ruboxistaurin (LY-333531) prevent long-term clozapine-induced weight gain through the inhibition of the lipid droplet-selective autophagy process ([@B100]). In summary, further studies focusing on the prediction model and drug combination are needed. Decreasing the adverse drug reaction will help improve the compliance of patients, ensure the therapeutic effect, and promote the life quality of them.
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